Silence Therapeutics plc

Listed Company

SLNCIK 0001479615NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsX0GB

Period

FY 2025

Revenue

$559.0K

Net Income

$-88.60M

Total Assets

$131.44M

Equity

$62.30M

Shares Out

141.70M

Op. Cash Flow

$-62.30M

Business

Silence Therapeutics plc is a biotechnology company that discovers and develops GalNAc-conjugated short interfering RNA (siRNA) therapeutics to silence disease-associated genes via RNA interference. It offers siRNA product candidates and platform services, including wholly owned clinical candidates divesiran (SLN124) for hematology/PV and zerlasiran (SLN360) for cardiovascular disease, plus partnered and preclinical programs from its proprietary mRNAi GOLD™ platform. Its business comprises a wholly owned pipeline, platform R&D and collaborative partnerships with pharmaceutical companies. It operates globally through clinical trials, third-party CDMOs and commercial partnership channels.

Summary from filing dated 2025-02-27

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31
Revenue	559,000	43	32	22
Cost of sales	−215,000	−12	−13	−13
Gross profit	344,000	31	19	8
Research and development costs	−68	−68	−57	−44
General and administrative expenses	−22	−27	−26	−26
Restructuring charges	−1	0	—	—
Operating loss	−91	−63	−64	−61
Foreign currency (loss)/gain, net	−8	646,000	−3	1
Other income, net	3	4	2	280,000
Benefit from R&D credit	7	14	12	10
Loss before income tax expense	−89	−44	−53	−50
Income tax expense	−11,000	−845,000	−956,000	−688,000
Net Loss	−89	−45	−54	−50
Loss per share basic	−0.63	−0.33	−0.49	−0.52
Loss per share diluted	−0.63	−0.33	−0.49	−0.52
Weighted-average shares outstanding basic	142	139	111	97
Weighted-average shares outstanding diluted	142	139	111	97

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	11	121	69	—	—
Short-term investments	74	26	—	—	—
R&D benefit receivable	22	24	22	—	—
Other current assets	12	15	12	—	—
Trade receivables	0	972,000	290,000	—	—
Total current assets	119	187	103	—	—
Property, plant and equipment, net	2	2	2	—	—
Operating lease right-of-use asset	167,000	157,000	370,000	—	—
Goodwill	11	9	10	10	—
Intangible assets	288,000	312,000	—	—	—
Other long-term assets	127,000	4	4	—	—
Total assets	131	203	119	—	—
Contract liabilities	−168,000	−306,000	−7	—	—
Trade and other payables	−13	−16	−16	—	—
Operating lease liabilities, current	−89,000	−117,000	−228,000	—	—
Total current liabilities	−14	−17	−22	—	—
Contract liabilities	−55	−52	−75	—	—
Operating lease liabilities, long-term	−71,000	0	−118,000	—	—
Total liabilities	−69	−69	−97	—	—
Commitments and contingencies (Note 21)	—	—	—	—	—
Ordinary shares - par value &#0.05 per share; 141,701,848 shares issued at December 31, 2025 (2024: 141,674,074)	−10	−10	−9	−8	—
Additional paid-in capital	−618	−610	−456	—	—
Accumulated deficit	563	474	432	—	—
Accumulated other comprehensive loss	3	12	11	—	—
Total shareholders' equity	−62	−134	−22	−27	−12
Total liabilities and shareholders' equity	−131	−203	−119	—	—

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31
Net loss after tax	−89	−45	−54	−50
Depreciation expense	300,000	300,000	400,000	400,000
Amortization expense	243,000	257,000	252,000	217,000
Share-based compensation expense	8	16	16	13
Net foreign exchange impacts	11	−3	4	−1
Other income, net	−3	−4	−2	−280,000
Income tax expense	11,000	845,000	956,000	688,000
Decrease/(increase) in trade receivables	1	−904,000	392,000	−723,000
Decrease/(increase) in other current assets	6	−1	2	−5
Decrease/(increase) in R&D benefit receivable	4	−2	−3	−10
Decrease in other long-term assets	4	—	−3	—
(Decrease)/increase in trade and other payables	−4	499,000	−473,000	2
Decrease in contract liabilities	−334,000	−29	−10	−5
Decrease in operating lease liabilities	−168,000	−165,000	−175,000	−235,000
Net cash used in operating activities	−62	−68	−49	−57
Redemption of term deposits	118	117	45	—
Purchase of term deposits	−166	−139	−26	−20
Purchase of property, plant and equipment	−55,000	−211,000	−56,000	−173,000
Net cash used in investing activities	−48	−22	19	−20
Proceeds from issue of ordinary shares	15,000	142	32	53
Net cash provided by financing activities	15,000	142	32	53
(Decrease)/increase in cash and cash equivalents	−110	52	2	−25
Effect of exchange rate fluctuations on cash and cash equivalents held	195,000	60,000	749,000	−8
Income Tax Paid net of refunds	−637,000	−433,000	−801,000	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro